1. Rituximab treatment of idiopathic membranous nephropathy
F.C. Fervenza, F.G. Cosio, S.B. Erickson, U. Specks, A.M. Herzenberg, J.J. Dillon, N. Leung, I.M. Cohen, D.N. Wochos, E. Bergstralh, M. Hladunewich, D.C. Cattran 
Kidney International 
Volume 73, Issue 1, Pages (January 2008)
DOI: /sj.ki
Copyright © 2008 International Society of Nephrology Terms and Conditions

2. Figure 1
Box plots of urine protein by months since start of rituximab therapy. The top and bottom of the box are the estimated 75th and 25th percentiles, respectively. The intermediate horizontal line and ‘+’ sign represent the median and mean urine protein, respectively. The vertical lines extend to the largest (smallest) data point, that is, within 1.5 times the interquartile range (75th–25th percentile) above the 75th percentile (or below the 25th). The number of patients with follow-up at 0, 1, 3, 6, 9, and 12 months are 15, 15, 15, 14, 14, and 14, respectively.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

3. Figure 2
Changes in serum IgG, IgA, and IgM levels following treatment with rituximab. *P<0.05.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

4. Figure 3
Dynamics of CD19+ B cells in patients with IMN versus RA versus ANCA-associated vasculitis. Patients with IMN and RA were treated with rituximab 1 g i.v. on days 1 and 15. Patients with ANCA-associated vasculitis received rituximab 375 mg m−2 i.v. on days 1, 8, 15, and 22.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions